![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. 1869118-25-1
2. 1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1h-pyrrole-3-carboxylic Acid
3. 1h-pyrrole-1,3-dicarboxylic Acid, 4-ethyl-2,5-dihydro-, 1-(phenylmethyl) Ester
4. Schembl18740435
5. Dtxsid001137343
6. Sb92a73z74
7. Db-162007
8. G71031
9. 1-(phenylmethyl) 4-ethyl-2,5-dihydro-1h-pyrrole-1,3-dicarboxylate
Molecular Weight | 275.30 g/mol |
---|---|
Molecular Formula | C15H17NO4 |
XLogP3 | 1.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 5 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 66.8 |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 410 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.